NEJM 4 23 2206 Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients.

This study investigates whether the antiviral treatment nirmatrelvir–ritonavir provides significant clinical benefits to vaccinated individuals at high risk for severe COVID-19. By comparing patients receiving the medication to those receiving standard care, researchers sought to determine if the drug reduced the likelihood of hospitalization or death. The results indicated that the treatment did not significantly lower these severe outcomes among populations with prior immunity from vaccines or previous infections, despite a measurable reduction in viral load. Ultimately, the findings suggest that the drug's effectiveness in preventing critical illness is vastly different for protected populations than it is for the unvaccinated.